Lennox-Gastaut Syndrome - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Lennox-Gastaut Syndrome - Pipeline Review, H1 2016

Lennox-Gastaut Syndrome - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Lennox-Gastaut Syndrome - Pipeline Review, H1 2016
Published May 31, 2016
60 pages — Published May 31, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Lennox-Gastaut Syndrome - Pipeline Review, H1 2016, provides an overview of the Lennox-Gastaut Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lennox-Gastaut Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lennox-Gastaut Syndrome and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lennox-Gastaut Syndrome
- The report reviews pipeline therapeutics for Lennox-Gastaut Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Lennox-Gastaut Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Lennox-Gastaut Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Lennox-Gastaut Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lennox-Gastaut Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding

  
Source:
Document ID
GMDHC8153IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Lennox-Gastaut Syndrome Overview61
Therapeutics Development72
  Pipeline Products for Lennox-Gastaut Syndrome Overview71
  Pipeline Products for Lennox-Gastaut Syndrome Comparative Analysis81
Lennox-Gastaut Syndrome Therapeutics under Development by Companies92
Lennox-Gastaut Syndrome Therapeutics under Investigation by Universities/Institutes111
Lennox-Gastaut Syndrome Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Lennox-Gastaut Syndrome Products under Development by Companies151
Lennox-Gastaut Syndrome Products under Investigation by Universities/Institutes161
Lennox-Gastaut Syndrome Companies Involved in Therapeutics Development173
  Eisai Co., Ltd.171
  GW Pharmaceuticals Plc181
  INSYS Therapeutics, Inc.191
Lennox-Gastaut Syndrome Therapeutics Assessment208
  Assessment by Monotherapy Products201
  Assessment by Target212
  Assessment by Mechanism of Action232
  Assessment by Route of Administration251
  Assessment by Molecule Type262
Drug Profiles2811
  cannabidiol - Drug Profile281
    Product Description281
    Mechanism of Action281
    R&D Progress283
  cannabidiol - Drug Profile311
    Product Description311
    Mechanism of Action311
    R&D Progress312
  NRP-2945 - Drug Profile331
    Product Description331
    Mechanism of Action331
    R&D Progress332
  perampanel - Drug Profile351
    Product Description351
    Mechanism of Action351
    R&D Progress353
  Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome - Drug Profile381
    Product Description381
    Mechanism of Action381
    R&D Progress381
Lennox-Gastaut Syndrome Recent Pipeline Updates3912
Lennox-Gastaut Syndrome Product Development Milestones518
  Featured News &Press Releases511
    Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals511
    Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy513
    Jun 11, 2015: GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study of Epidiolex in Lennox-Gastaut Syndrome541
    May 11, 2015: GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex (CBD) in Lennox-Gastaut Syndrome541
    Apr 23, 2015: Insys Therapeutics Commences Dosing in Phase 1/2 Safety and Pharmacokinetic Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients551
    Jan 12, 2015: Insys Therapeutics To Initiate Phase III study For An Epileptic Drug561
    Dec 05, 2014: Eisai Presents New Data on Rufinamide at the 68th Annual American Epilepsy Society Meeting561
    Oct 15, 2014: U.S. FDA Accepts Eisai's sNDA for BANZEL (Rufinamide) as Adjunctive Treatment in Pediatric Patients With Lennox-Gastaut Syndrome571
    Jun 25, 2014: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Rare Form of Epilepsy, Lennox-Gastaut Syndrome571
    May 07, 2014: GW Pharmaceuticals Receives Investigational New Drug From FDA for Phase 2/3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome581
Appendix592
  Methodology591
  Coverage591
  Secondary Research591
  Primary Research591
  Expert Panel Validation591
  Contact Us591
  Disclaimer601

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Lennox-Gastaut Syndrome - Pipeline Review, H1 2016" May 31, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Lennox-Gastaut-Syndrome-Pipeline-Review-H1-2016-2088-15904>
  
APA:
Global Markets Direct - Market Research. (2016). Lennox-Gastaut Syndrome - Pipeline Review, H1 2016 May 31, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Lennox-Gastaut-Syndrome-Pipeline-Review-H1-2016-2088-15904>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.